Geode Capital Management’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Geode Capital Management’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-190,240	Closed	-$165K	–	4260
2019 Q2	$165K	Sell	190,240 -38,291	-17%	-$59.9K	﹤0.01%	3839
2019 Q1	$530K	Buy	228,531 +60,312	+36%	+$163K	﹤0.01%	3419
2018 Q4	$390K	Buy	168,219 +6,699	+4%	+$59.1K	﹤0.01%	3461
2018 Q3	$2.39M	Buy	161,520 +75,706	+88%	+$1.2M	﹤0.01%	2789
2018 Q2	$1.3M	Buy	85,814 +16,313	+23%	+$277K	﹤0.01%	3071
2018 Q1	$1.3M	Buy	69,501 +24,348	+54%	+$426K	﹤0.01%	2994
2017 Q4	$819K	Buy	45,153 +5,499	+14%	+$116K	﹤0.01%	3177
2017 Q3	$882K	Buy	+39,654	New	+$870K	﹤0.01%	3172

Other funds holding SNNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Geode Capital Management's SNNA Position: Q3 2019 in Review

Geode Capital Management sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q3 2019, closing a stake of 190,240 shares — an estimated $165K sold.

Geode Capital Management first reported a position in SNNA in Q3 2017 and held it in 8 quarters. The position peaked at $2.39M in Q3 2018. 23 funds tracked by Wall St. Rank hold SNNA as of Q3 2019.

Geode Capital Management reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Geode Capital Management sold 190,240 Sienna Biopharmaceuticals, Inc. shares in Q3 2019, an estimated $165K.
Geode Capital Management first reported a position in Sienna Biopharmaceuticals, Inc. in Q3 2017 and held it in 8 quarters.
Geode Capital Management's Sienna Biopharmaceuticals, Inc. position peaked at $2.39M in Q3 2018.
23 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q3 2019.

Based on Geode Capital Management's 13F filing for Q3 2019, filed 12 Nov 2019.